Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825377 | 0.83 | HRH1 (0.56) | TAAR1HTR2AGABBR2GABBR1CHRNB2 | |
| SCHEMBL10627463 | 0.81 | CYP2D6 (0.42) | TAAR1HTR2AHRH1CYP2D6DPP4 | |
| SCHEMBL23522330 | 0.78 | CYP2A6 (0.38) | TAAR1 | |
| SCHEMBL15653584 | 0.78 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10584869 | 0.77 | CYP2D6 (0.39) | TAAR1HTR2ACYP2D6 | |
| SCHEMBL6817626 | 0.77 | CYP2D6 (0.39) | TAAR1HTR2AHRH1CYP2D6DPP4 | |
| SCHEMBL218804 | 0.77 | LMNA (0.46) | TAAR1HTR2AHRH1CYP2D6 | |
| SCHEMBL2001329 | 0.77 | CYP2D6 (0.39) | TAAR1HTR2AHRH1CYP2D6DPP4 | |
| SCHEMBL19233902 | 0.77 | TAAR1 (0.52) | TAAR1HTR2AGABBR2GABBR1CHRNB2 | |
| SCHEMBL4553372 | 0.77 | TAAR1 (0.52) | TAAR1HTR2AGABBR2GABBR1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370782-A | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | CN | claimed |
| WO-1994014788-A1 | NOVEL DERIVATIVES OF A FIVE-MEMBERED RING FUSED BENZENE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1994-07-07 | — | — | WO | claimed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3175863-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-RE48267-E1 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3175863-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20170051033-A1 | Variants of C-Type Natriuretic Peptide | BIOMARIN PHARM INC (US) | 2017-02-23 | — | — | US | disclosed |
| CN-104185624-B | Antiviral compound | 弗·哈夫曼-拉罗切有限公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-2432489-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-101255131-A | Heterocyclic derivatives as opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-03 | — | — | CN | disclosed |
| CN-101007815-A | Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2007-08-01 | — | — | CN | disclosed |
| CN-1976922-A | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| CN-1665501-A | heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-07 | — | — | CN | disclosed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | disclosed |
| CN-1479618-A | Treatment of sexual dysfunction with bombesin antagonists | ����-�����ع�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | TAAR1 1824/4885HTR2A 4343/4885GABBR2 2762/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | TAAR1 1920/4885HTR2A 4391/4885GABBR2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.